We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

104 hedge funds and large institutions have $694M invested in Aclaris Therapeutics in 2017 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 56 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 23

5.1% more ownership

Funds ownership: 90.71% → 95.81% (+5.1%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

2% less capital invested

Capital invested by funds: $707M → $694M (-$12.8M)

5% less funds holding

Funds holding: 110 → 104 (-6)

25% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 24

Holders
104
Holders Change
-6
Holders Change %
-5.45%
% of All Funds
2.59%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
18
Increased
56
Reduced
23
Closed
24
Calls
$3.8M
Puts
–
Net Calls
+$3.8M
Net Calls Change
+$525K

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$27.4M
2
Franklin Resources
Franklin Resources
California
+$19M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$15.1M
4
BlackRock
BlackRock
New York
+$11.4M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$10.9M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$37.6M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$13.4M
3
EC
EcoR1 Capital
California
-$13.3M
4
RSCM
Rock Springs Capital Management
Maryland
-$6.39M
5
Fidelity International
Fidelity International
Bermuda
-$5.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$6.85M +$1.62M +59,726 +31%
TCIM
27
TIAA CREF Investment Management
New York
$5.83M +$997K +36,667 +21%
EC
28
EcoR1 Capital
California
$5.03M -$13.3M -487,628 -72%
HighTower Advisors
29
HighTower Advisors
Illinois
$3.9M +$1.85K +68 +0%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$3.9M +$698K +25,661 +22%
EAM
31
Eventide Asset Management
Massachusetts
$3.8M – – –
Deutsche Bank
32
Deutsche Bank
Germany
$3.24M +$798K +29,368 +33%
UBS AM
33
UBS AM
Illinois
$2.98M +$2.99M +110,037 New
CWG
34
C WorldWide Group
Denmark
$2.62M +$411K +15,100 +19%
RG
35
Redmile Group
California
$2.56M +$105K +3,860 +4%
ACP
36
Acuta Capital Partners
California
$2.44M -$2.99M -110,000 -55%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.39M +$2.09K +77 +0.1%
Bank of America
38
Bank of America
North Carolina
$2.33M +$2.28M +83,735 +4,103%
Goldman Sachs
39
Goldman Sachs
New York
$2.17M +$1.23M +45,305 +130%
KCM
40
Kennedy Capital Management
Missouri
$2.03M +$2.04M +74,962 New
AI
41
Axiom Investors
Connecticut
$1.9M +$71.8K +2,641 +4%
GPCM
42
Granite Point Capital Management
Massachusetts
$1.78M – – –
Charles Schwab
43
Charles Schwab
California
$1.68M +$484K +17,804 +40%
JGC
44
J. Goldman & Co
New York
$1.65M +$329K +12,100 +25%
SCM
45
Suffolk Capital Management
New York
$1.47M +$1.47M +54,244 New
RCAMU
46
Rothschild & Co Asset Management US
Connecticut
$1.38M -$62.6K -2,301 -4%
MCM
47
Moore Capital Management
New York
$1.36M -$340K -12,500 -20%
Lazard Asset Management
48
Lazard Asset Management
New York
$1.27M -$43.5K -1,600 -3%
MIM
49
Monashee Investment Management
Massachusetts
$1.24M +$1.24M +45,740 New
RHJA
50
Rice Hall James & Associates
California
$1.16M +$219K +8,042 +23%
1
2
3 4 5

ACRS Hedge Fund Activity: Q2 2017 in Review

104 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2017, worth a combined $694M — down 1.8% from $707M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ACRS and 18 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 56 added.

The largest buyer was Eagle Asset Management, adding an estimated $27.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $37.6M sold.

  • 104 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2017, down from 110 in Q1 2017.
  • Funds reported $694M of Aclaris Therapeutics stock for Q2 2017, down 1.8% quarter-over-quarter.
  • 18 funds opened new Aclaris Therapeutics positions in Q2 2017 and 24 closed out, a net change of -6 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2017 was Eagle Asset Management, an estimated $27.4M added.
  • The largest Aclaris Therapeutics seller in Q2 2017 was Perceptive Advisors, an estimated $37.6M sold.

Based on aggregated 13F filings for Q2 2017.